| VAP Mortality | Control Mortality | Difference | |
| Bercault 2001([FOOTNOTE=Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med. 2001;29(12):2303-2309. ],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805224]) (p< 0.0001) |
41.00% | 14.00% | 27.00% |
| Warren 2003([FOOTNOTE=Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med. 2003;31(5):1312-1317.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=277904]) (p< 0.001) |
50.00% | 34.00% | 16.00% |
| Rello 2002([FOOTNOTE=Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002;122(6):2115-2121.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805225]) (p< 0.713) |
30.50% | 30.40% | 0.10% |
| Ibrahim 2001([FOOTNOTE=Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH. The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes. Chest. 2001;120(2):555-561. ],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805222]) (p< 0.004) |
45.50% | 32.20% | 13.30% |
| Kollef 2005([FOOTNOTE=Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128(6):3854-3862.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=805226]) (p< 0.0001) |
29.30% | 10.00% | 19.30% |
| Attributable Mortality | |
| Bekaert 2011([FOOTNOTE=Bekaert M, Timsit JF, Vansteelandt S, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011;184(10):1133-1139. ],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=476875]) (30 Day) |
4.40% |
| Bekaert 20116 (60 Day) |
5.90% |
| VAP Hospital LOS | Control Hospital LOS | Difference | |
| Warren 20032 (p< 0.001) |
38 | 13 | 25 |
| Rello 20023 (p< 0.001) |
25.5 | 14 | 11.5 |
| Kollef 20055 (p< 0.0001) |
23 | 7.5 | 15.5 |
| VAP ICU LOS | Control ICU LOS | Difference | |
| Bercault 20011 (p< 0.0001) |
31 | 26 | 5 |
| Warren 20032 (p< 0.001) |
26 | 4 | 22 |
| Rello 20023 (p< 0.001) |
11.7 | 5.6 | 6.1 |
| VAP Costs | Control Costs | Difference | |
| Warren 20032 (p< 0.001) |
$70,568 | $21,620 |
$48,948 |
| Rello 20023 (p< 0.001) |
$104,983 | $63,689 | $41,294 |
| Kollef 20055 (p< 0.0001) |
$150,841 | $25,218 | $125,623 |
| Hugonnet 2004([FOOTNOTE=Hugonnet S, Eggimann P, Borst F, Maricot P, Chevrolet JC, Pittet D. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol. 2004;25(12):1090-1096.],[ANCHOR=View Abstract],[LINK=/content/covidien/websites/medtronic/com/en/covidien/support/clinical-evidence.html?id=277906]) (p< 0.001) |
$24,727 | $17,438 | $7,289 |